Franklin Resources Inc. decreased its holdings in shares of Loxo Oncology, Inc. (NASDAQ:LOXO) by 39.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 381,097 shares of the biopharmaceutical company’s stock after selling 250,389 shares during the quarter. Franklin Resources Inc. owned about 1.46% of Loxo Oncology worth $30,560,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Aisling Capital LLC raised its holdings in Loxo Oncology by 4.0% during the 1st quarter. Aisling Capital LLC now owns 4,188,920 shares of the biopharmaceutical company’s stock valued at $176,270,000 after acquiring an additional 160,000 shares during the period. Bank of America Corp DE raised its holdings in Loxo Oncology by 162.6% during the 1st quarter. Bank of America Corp DE now owns 8,176 shares of the biopharmaceutical company’s stock valued at $344,000 after acquiring an additional 5,063 shares during the period. Driehaus Capital Management LLC raised its holdings in Loxo Oncology by 41.5% during the 1st quarter. Driehaus Capital Management LLC now owns 598,863 shares of the biopharmaceutical company’s stock valued at $25,200,000 after acquiring an additional 175,587 shares during the period. Swiss National Bank raised its holdings in Loxo Oncology by 53.5% during the 1st quarter. Swiss National Bank now owns 28,700 shares of the biopharmaceutical company’s stock valued at $1,208,000 after acquiring an additional 10,000 shares during the period. Finally, Federated Investors Inc. PA raised its holdings in Loxo Oncology by 21,561.6% during the 2nd quarter. Federated Investors Inc. PA now owns 37,258 shares of the biopharmaceutical company’s stock valued at $2,988,000 after acquiring an additional 37,086 shares during the period.

TRADEMARK VIOLATION WARNING: “Franklin Resources Inc. Has $30.56 Million Holdings in Loxo Oncology, Inc. (LOXO)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/19/franklin-resources-inc-has-30-56-million-holdings-in-loxo-oncology-inc-loxo.html.

LOXO has been the topic of a number of analyst reports. Cowen and Company reissued an “outperform” rating on shares of Loxo Oncology in a report on Monday, June 5th. BidaskClub cut shares of Loxo Oncology from a “hold” rating to a “sell” rating in a report on Friday, August 4th. JMP Securities cut shares of Loxo Oncology from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $83.12 to $17.14 in a report on Tuesday, August 29th. They noted that the move was a valuation call. Citigroup Inc. raised shares of Loxo Oncology from a “neutral” rating to a “buy” rating and set a $86.00 target price on the stock in a report on Monday, June 5th. Finally, Zacks Investment Research raised shares of Loxo Oncology from a “sell” rating to a “hold” rating in a report on Thursday, June 8th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Loxo Oncology currently has a consensus rating of “Buy” and an average target price of $70.73.

Loxo Oncology, Inc. (LOXO) opened at 88.72 on Tuesday. The stock has a 50 day moving average of $76.53 and a 200 day moving average of $61.65. The company’s market cap is $2.65 billion. Loxo Oncology, Inc. has a 12-month low of $17.14 and a 12-month high of $91.00.

Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.99) by ($0.15). During the same quarter in the previous year, the company posted ($0.77) EPS. Equities analysts expect that Loxo Oncology, Inc. will post ($4.54) earnings per share for the current year.

In other news, CEO Joshua H. Bilenker sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $73.56, for a total transaction of $1,103,400.00. Following the sale, the chief executive officer now directly owns 196,207 shares in the company, valued at approximately $14,432,986.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Naarden Jacob Van sold 1,541 shares of the firm’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $73.73, for a total transaction of $113,617.93. Following the sale, the insider now owns 1,541 shares in the company, valued at $113,617.93. The disclosure for this sale can be found here. Insiders have sold a total of 51,073 shares of company stock worth $3,847,662 over the last 90 days. Insiders own 27.80% of the company’s stock.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Stock Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related stocks with our FREE daily email newsletter.